Alzamend Neuro, Inc.
ALZN

NASDAQ > Biotechnology
DCF:$0.11  |   P/E: -
$0.14(-11.20%)
Change
Rating:
Price: $1.25 USD
Market Cap: $6.03M

...Loading ALZN Peers...





Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

    4 Employees

    CEO : Mr. Stephan Jackman

    Address : 3500 Lenox Road NE, Atlanta,GA, US, - 30326,

Key ExcutivesDesignation
Mr. Kenneth S. Cragun CPASenior Vice President of Finance
Mr. Stephan JackmanChief Executive Officer & Director
Mr. Milton Charles Ault IIIFounder & Vice Chairman
Mr. David J. KatzoffChief Financial Officer
Mr. Henry C. W. Nisser Esq.Executive Vice President, General Counsel & Director